autarkize | $2,502,492 | (Nov 1, 2024)
Keel | $5,933,454 | (Nov 1, 2024)
Decart | $21,000,000 | (Nov 1, 2024)
NextPoint Therapeutics, Inc.
- 15/02/2024
- Series B
- $42,500,000
Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis discovered by our scientist founders. Our goal is to deliver new options to people with cancer.
- Industry Biotechnology
- Website https://nextpointtx.com/
- LinkedIn https://www.linkedin.com/company/nextpoint-therapeutics/
Related People
Ivan CheungFounder
United States -
Scarsdale, New York
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 checkpoint axis. Our innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. NextPoint is simultaneously advancing therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology and beyond.
OpenOrigins | $4,500,000 | (Nov 1, 2024)
MOTORMIA | $8,000,000 | (Nov 1, 2024)
MealMe, Inc. | $8,000,000 | (Nov 1, 2024)
Persperity Health, Inc | $1,000,000 | (Nov 1, 2024)
Persana AI | $2,300,000 | (Nov 1, 2024)
Ataraxis AI | $4,000,000 | (Nov 1, 2024)
Definition Health | $7,412,756 | (Nov 1, 2024)
LINGO | $2,250,000 | (Nov 1, 2024)
ContraForce | $3,250,000 | (Nov 1, 2024)